CYCC
$0.74
Cyclacel Pharmaceuti
($.01)
(1.33%)
CYCC
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.15)
Revenue:  N/A
Wednesday
Feb 12
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CYCC reports earnings?
Beat
Meet
Miss

Where is CYCC's stock price going from here?
Up
Flat
Down
Stock chart of CYCC
Analysts
Summary of analysts' recommendations for CYCC
Score
Grade
Pivots
Resistance
$0.93
$0.86
$0.81

$0.74

Support
$0.68
$0.61
$0.56
Tweet
Growth
Description
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.